When was Delfi Diagnostics founded?

Delfi Diagnostics was founded in 2019 and raised its 1st funding round within a year of its incorporation.

Where is Delfi Diagnostics located?

Delfi Diagnostics is headquartered in Baltimore, United States. It is registered at 1999 BRYAN ST STE 900,DALLAS,TX,75201,57.

Who is the current CEO of Delfi Diagnostics?

Susan Tousi of Delfi Diagnostics.

Which legal entities is Delfi Diagnostics associated with?

Delfi Diagnostics is associated with DELFI DIAGNOSTICS, INC..

How many employees does Delfi Diagnostics have?

As of Aug 31, 2026, the latest employee count at Delfi Diagnostics is 151.

Is Delfi Diagnostics a funded company?

Delfi Diagnostics is a funded company, having raised a total of $332M across 6 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jun 18, 2018.

How much is Delfi Diagnostics worth?

The latest valuation of Delfi Diagnostics is $***** as of Nov 01, 2023.

When was the latest funding round of Delfi Diagnostics?

Delfi Diagnostics' latest funding was a $***** Conventional Debt round on Dec 01, 2025, with participation from 0 investor. Its primary sector is Clinical Genomics. In United States, the Clinical Genomics sector has seen $458M in funding in 2026 to date.

Where does Delfi Diagnostics rank among its competitors?

Delfi Diagnostics ranks 12th amongst 538 active competitors, of which 156 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was GRAIL, which secured $110M in Jun, 2026.

Who are the top competitors of Delfi Diagnostics?

Delfi Diagnostics' top competitors include Natera, Guardant Health and GRAIL. Among them, GRAIL secured the most recent funding round in June, 2026.

Delfi Diagnostics - 2026 Company Profile, Team, Funding & Competitors

Delfi Diagnostics is a series B company based in Baltimore (United States), founded in 2019. It operates as a Provider of DNA sequencing for cancer detection. Delfi Diagnostics has raised $332M in funding from investors like Orbimed, DFJ Growth and Merck Global Health Innovation Fund, with a current valuation of $*****. The company has 538 active competitors, including 156 funded and 114 that have exited. Its top competitors include companies like Natera, Guardant Health and GRAIL.

Company Details

Provider of DNA sequencing for cancer detection. The company's platform uses artificial intelligence and whole genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients with cancer.

Website: delfidiagnostics.com
Social
Email ID: *****@delfidiagnostics.com
Phone Number: +1 **********
Registered Address: 1999 BRYAN ST STE 900,DALLAS,TX,75201,57

Key Metrics

Founded Year

2019

Location

Baltimore, United States

Stage

Series B

Total Funding

$332M in 6 rounds

Latest Funding Round

Conventional Debt, Dec 01, 2025, $*****

Post Money Valuation

$***** as on Nov 01, 2023

Investors

Orbimed & 20 more

Ranked

12^th among 538 active competitors

Employee Count

151 as on Aug 31, 2026

Similar Companies

Natera & 667 more

View Delfi Diagnostics' full profile

Delfi Diagnostics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
DELFI DIAGNOSTICS, INC. CIN: 32089374113 , United States, Active	Apr 11, 2023	-	-	-

Delfi Diagnostics has raised a total funding of $332M over 6 rounds. Its first funding round was on Jun 18, 2018. Delfi Diagnostics has 21 institutional investors.

Here is the list of recent funding rounds of Delfi Diagnostics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 01, 2025	3844723	Conventional Debt	7593705	5980919	9279413	2650628
Jun 05, 2024	9447438	Series B	8107965	8259103	6175969	2743859
Jul 18, 2022	8131153	Series B	3362989	3831464	DFJ Growth	Lilly & 11 more

Access funding benchmarks and valuations. Sign up today!

View details of Delfi Diagnostics's funding rounds and investors

Here are the details of Delfi Diagnostics' key team members:

Susan Tousi: CEO of Delfi Diagnostics.
Contact Info: 1 email address

Delfi Diagnostics' Board of Directors

Delfi Diagnostics's board has 13 active members. Rishi Gupta, Justin Kao, William Stevens, Greg Yap, Peter Bach, Elizabeth Homans, Michael Dybbs, William J. Stevens, Jennifer Buechel, Nicholas Dracopoli, Douglas Schenkel, Jacob Van Naarden and Victor Velculescu are independent board members.

Here is the list of Delfi Diagnostics' board of directors:

Name	Type	Representing	Status	Duration
Rishi Gupta	Independent board member	-	Current	4y 2m
bqplkhm	Independent board member	-	Current	8y 4m
neuiftn	Independent board member	-	Current	8y 8m
roieqzv	Independent board member	-	Current	7y 9m
yfwiaus	Independent board member	-	Current	2y 9m
cpwyjkp	Independent board member	-	Current	8y 6m
zjfxrrx	Independent board member	-	Current	5y 5m
wl{wke{	Independent board member	-	Current	4y 3m
whwizyz	Independent board member	-	Current	5y 3m
f{nfgzo	Independent board member	-	Current	3y 8m
qyilfoi	Independent board member	-	Current	4y 3m
orvsroh	Independent board member	-	Current	1y 5m
roffyrc	Independent board member	-	Current	4y 6m

View details of Delfi Diagnostics's Founder profiles and Board Members

Delfi Diagnostics' employee count trend

Delfi Diagnostics has 151 employees as of Aug 26. Here is Delfi Diagnostics's employee count trend over the years:

Employee count trend for Delfi Diagnostics

Uncover Delfi Diagnostics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Delfi Diagnostics include Natera, Guardant Health and GRAIL. Here is the list of Top 10 competitors of Delfi Diagnostics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Natera 2004, Redwood City (United States), Public	Developer of cell-free DNA testing for oncology, women’s health, and organ health	$152M	Harmony Partners, Bain Capital Life Sciences ... & 18 others	80/100
2nd	Guardant Health 2012, Redwood City (United States), Public	Developer of digital sequencing technology for cancer detection	$557M	SoftBank Vision Fund, Lightspeed Venture Partners ... & 25 others	79/100
3rd	GRAIL 2016, Menlo Park (United States), Public	Developer of a screening platform for circulating tumor DNA to detect cancer	$2B	Arch Venture Partners, Hillhouse & 52 others	78/100
4th	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Coatue & 19 others	71/100
5th	Foundation Medicine 2010, Cambridge (United States), Acquired	Provider of genomics-based diagnostics test for cancer	$96.5M	Redmile Group, Deerfield & 11 others	70/100
6th	Prenetics 2009, Hong Kong (China), Public	Online platform for genetic and diagnostic health testing that helps identify health risks	$67.6M	Apis Partners, Beyond Ventures & 22 others	69/100
7th	BillionToOne 2015, San Francisco (United States), Public	Provider of cell-free cancer liquid biopsy test	$389M	Hummingbird Ventures, Adams Street Partners ... & 31 others	69/100
8th	Foresight Diagnostics 2020, Aurora (United States), Acquired	Developer of minimally-invasive liquid biopsy test for the detection of cancer	$104M	Foresite Capital, Bluebird Ventures & 6 others	66/100
9th	Scipher Medicine 2014, Waltham (United States), Series D	Provider of precision medicine based on liquid biopsy test	$233M	Northpond Ventures, Cowen & 14 others	65/100
10th	Myriad Genetics 1991, United States, Public	Developer of molecular diagnostics and personalized medicine for cancer	-	Grayhawk Capital, TriplePoint Capital & 6 others	64/100
12th	Delfi Diagnostics 2019, Baltimore (United States), Series B	Provider of DNA sequencing for cancer detection	$332M	Foresite Capital, Point72 & 19 others	63/100